Visit PreciGenome at ASGCT 2026 in Boston — Booth #1363

Pre-conference announcement | ASGCT 29th Annual Meeting | May 11–15, 2026 | Boston Convention & Exhibition Center | Booth #1363

PreciGenome is pleased to announce our participation in the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting, taking place May 11–15, 2026 at the Boston Convention & Exhibition Center in Boston, Massachusetts.

ASGCT is the world's premier scientific gathering for the gene and cell therapy community, bringing together academic investigators, clinical researchers, biotech innovators, and pharmaceutical leaders to share the latest breakthroughs in genetic medicine. We're proud to be exhibiting at this year's meeting and invite all attendees to visit us at Booth #1363.

What to See at the PreciGenome Booth

Our team will showcase the microfluidic platforms and contract services that are accelerating gene & cell therapy programs from early discovery through preclinical development.

NanoGenerator® LNP / mRNA-LNP Synthesis Platform

Lipid nanoparticles have become the delivery vehicle of choice for mRNA vaccines, gene-editing payloads, and a growing class of nucleic-acid therapeutics. PreciGenome's NanoGenerator® platform — including the Flex-S, Flex-M, and Spark-XS systems — uses microfluidic mixing to produce highly uniform LNPs with low polydispersity index (PDI), reproducible encapsulation efficiency, and seamless scaling from milligram screening to gram-scale GMP-ready production. The platform supports mRNA, siRNA, ASO, plasmid DNA, CRISPR ribonucleoproteins, and PLGA nanoparticles. Stop by for a live demonstration and learn how researchers are using NanoGenerator® to streamline their LNP formulation workflow.

LNP CRO & mRNA-LNP Contract Services

Beyond instrumentation, PreciGenome offers end-to-end LNP and mRNA-LNP contract services for academic and industry teams that want to outsource formulation work. Our service portfolio includes lipid library screening, formulation optimization, mRNA synthesis, antibody-conjugated targeted LNPs, in-vitro transfection studies, and in-vivo PK/biodistribution support. Whether you need a pilot batch for a proof-of-concept study or scale-up support for IND-enabling work, our experienced formulation team can help shorten your development timeline.

Digital PCR Systems

Accurate nucleic acid quantification is essential to gene therapy QC, AAV titer measurement, lentivirus integration analysis, and rare-variant detection in cell therapy programs. PreciGenome's microfluidic-based digital PCR platform delivers the sensitivity and reproducibility that demanding CGT applications require. Visit the booth to see our latest digital PCR instruments and assay kits.

Organ-on-Chip Systems

Predicting how a candidate therapy will behave in human tissue is one of the toughest challenges in translational research. PreciGenome's organ-on-chip systems use advanced microfluidic cell perfusion technology to recreate organ-level function on a chip — enabling more predictive drug screening, toxicity testing, and disease modeling for gene and cell therapy programs. Our team will walk you through case studies and discuss how these platforms can complement your in-vitro and in-vivo workflows.

Meet Our Team

Whether you're optimizing an mRNA-LNP candidate, building a CGT manufacturing process, exploring novel delivery chemistries, or evaluating better preclinical models, our application scientists and business development team will be available throughout the meeting to discuss your specific research needs and how PreciGenome can support your program.

Event Details

Event: ASGCT 29th Annual Meeting

Dates: May 11–15, 2026

Booth: #1363

Location: Boston Convention & Exhibition Center, Boston, MA

Website: www.precigenome.com

We look forward to connecting with the gene and cell therapy community in Boston. See you at ASGCT 2026!